A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction.

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Abstract Text:

Jaggi Rao,Michael H Gold,Mitchel P Goldman,

Introduction Cellulite is the unsightly dimpling and nodularity found on the thighs and buttocks of many postadolescent women. Unfortunately, poor understanding of its pathophysiology coupled with very few scientifically based studies have left us with limited treatment options that are tolerable and effective. Purpose To review current concepts of the etiology and nature of cellulite and summarize available treatment options. To evaluate a novel, pathophysiologically based, topical agent for treatment. Materials and methods A total of 40 women with a moderate degree of cellulite (20 from each of the two research centers) entered a double-blinded, randomized trial where an anticellulite cream was applied on a nightly basis to the affected sites for four continuous weeks. Each subject was randomized to receive active cream on either the right or left leg, with the contralateral side serving as placebo control. Bioceramic-coated neoprene shorts were worn overnight to enhance penetration of the topical agents by occlusion. High-quality digital photography was taken before treatment and after 4 weeks, with tangential full-spectrum lighting. Five blinded, independent physician reviewers assessed the photographs for improvement. Subject questionnaires were completed to assess tolerability and efficacy. Results Of the 34 subjects who completed the study, 62% (21/34) noticed an overall improvement in their cellulite, with 62% (13/21) reporting greater improvement in the thigh that received active product. All 34 subjects found the shorts and creams easy and pleasant to use. Overall, the average measured decrease in thigh circumference was 1.9 cm (range: 0.1-4.5) with active product, and 1.3 cm (range: 0.1-3.0) with placebo. Upon review of the pre- and poststudy photographs, dermatologist evaluators found thighs treated with active product showed greater improvement than thighs treated with placebo in 68% of subjects. Conclusions The active topical agent used in this study was found to be effective in reducing the appearance of cellulite. All subjects tolerated the formulation well with no adverse effects. The success of this research validates the pathophysiologic concepts used to formulate the topical compound. This study both increases our understanding of the nature of cellulite and establishes a tolerable, effective product to treat it.

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Publishing Authors By Initials

J Rao,MH Gold,MP Goldman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of cosmetic dermatology

VOLUME: 4

Page Numbers: 93-102

Journal Abbreviation:

ISSN: 1473-2165

DAY: 14

MONTH: Jun

YEAR: 2005

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101130964

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction.

AFFILIATION: Dermatology/Cosmetic Laser Associates of La Jolla, Inc., La Jolla, California.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Cosmet Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction Related Publications

• A two-center, double-blinded, randomized trial testing the tolerability and efficacy of a novel therapeutic agent for cellulite reduction.
• Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade.
• An alpha-(1,4)-amylase is essential for alpha-(1,3)-glucan production and virulence in Histoplasma capsulatum.
• An integrated approach to the management of chronic myeloid leukemia.
• Cardiac concussion (commotio cordis).
• Classification of Impulse Oscillometric Patterns of Lung Function in Asthmatic Children using Artificial Neural Networks.
• Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
• Defining virulence genes in the dimorphic fungi.
• Do biomarkers of stress mediate the relation between socioeconomic status and health?
• Dorsal radial glia generate olfactory bulb interneurons in the postnatal murine brain.
• Evaluation of respiratory system models based on parameter estimates from impulse oscillometry data.
• Experimental design criteria in phylogenetics: where to add taxa.
• Glial progenitor-based repair of demyelinating neurological diseases.
• Histoplasma capsulatum alpha-(1,3)-glucan blocks innate immune recognition by the beta-glucan receptor.
• Intravascular lasers in the treatment of varicose veins.
• Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F).
• Modeling human respiratory impedance. Comparing the best method with the least estimation errors.
• Neurocytoma is a tumor of adult neuronal progenitor cells.
• Parasitic infections of the skin.
• Peak selection from MALDI-TOF mass spectra using ant colony optimization.
• Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western Kenya.
• Risk factors for physical assault and rape among six Native American tribes.
• Saliva from subjects harboring Actinobacillus actinomycetemcomitans kills Streptococcus mutans in vitro.
• Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library.
• Serologic evidence for regional differences in pediatric cryptococcal infection.
• Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.
• The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
• Using Q-methodology to understand perceived fatigue reported by adolescents with cancer.
• Using ancestry-informative markers to define populations and detect population stratification.
• Women's Health Initiative Perspective: What Does It Really Mean to the Rheumatologist?